Global AMR R&D Hub

The Global Antimicrobial Resistance Research and Development Hub, or Global AMR R&D Hub for short, is supporting evidenced based decision making on where efforts and resources may be best allocated for AMR R&D.

The current effort to finance R&D of new antimicrobials, diagnostics and vaccines to address AMR remains insufficient and needs to be intensified at global level. There was until now no quality data on investments in this area, nor was it possible to produce information for the whole One Health spectrum. Based on this observation the leaders of the G20 countries launched a call in 2017 for a new global centre to address these challenges and enhance collaboration and coordination in global AMR R&D using a One Health approach.

Official launching in Geneva

The Global AMR R&D Hub was officially launched in Geneva in May 2018 on the margins of the 71st World Health Assembly. Open to non-G20 countries and non-governmental donor organisations, it is governed by a Board of Members composed of currently twenty members and four observers (*). Its secretariat is based in Berlin. Switzerland considers that the issue of AMR R&D must be tackled at international level and therefore joined the Hub at its inception and supports its activities.
The Global AMR R&D Hub objective is to collect and present information on AMR R&D investments, products in the pipeline and market interventions. This information is intended for countries, foundations, organisations and initiatives to help set priorities and maximise the impact of resources invested in R&D to mitigate the AMR threat. The Hub's activities are part of a comprehensive One Health approach encompassing human and animal health and, from March 2021, plant and environmental health.

Dynamic Dashboard  

In March 2020, the Global AMR R&D Hub launched its Dynamic Dashboard. This tool brings together information about investments in AMR R&D on human bacterial and animal infections from 130 public and philanthropic funders. The 5.6 billion US $ or 4.9 billion € investment since 2017 represents funding to 62 countries on five continents. The level of investment and international partnerships developing is encouraging; however, more needs to be done.
Consolidated information on AMR R&D provided by the Dynamic Dashboard and resulting analyses is intended to assist with the identification of global AMR R&D priorities. Over time, the information provided and further activities of the Global AMR R&D Hub will help to support and improve coordination and collaboration in AMR R&D. This will be assisted by the Hub’s effort to strengthen awareness at high political levels of the role of R&D to address AMR.

Incentives Gallery

In June 2019, the G20 leaders tasked the Hub to analyse push and pull incentive mechanisms, and identify best models for AMR R&D. The Hub has commissioned several studies on such incentives, and results are expected in autumn 2020. In addition, it has launched in August 2020 a new gallery on incentives in the Dynamic Dashboard. This landscape analysis shows where and how governments and organisations across the globe are supporting and facilitating through incentives the development of both old and new antibiotics.

With its Dynamic Dashboard using a One Health approach and its activities on incentives, the Global AMR R&D Hub shows that it is now playing its part in addressing the global issue of AMR.

(*) Members: Australia, Canada, China, European Commission, Bill & Melinda Gates Foundation, Germany, France, India, Italy, Japan, The Netherlands, Norway, Russia, Spain, Sweden, Switzerland, Turkey, United Kingdom, USA, Wellcome Trust. Observers: WHO, OIE, FAO, OECD.

Last modification 08.09.2020

Top of page

Foto Mitgliederrat Global AMR

Face-to-face meeting of the Hub’s Board of Members in Paris in October 2019 (© Global AMR R&D Hub)